Market Trends of Global Porcine Vaccine Industry
This section covers the major market trends shaping the Porcine Vaccine Market according to our research experts:
Porcine Circovirus Associated Disease is Expected to Witness a Healthy Growth
PCV (Porcine Circovirus) is the smallest non-enveloped, single-stranded DNA virus, which replicates autonomously in eukaryotic cells, using the host polymerase for genome amplification. PCV can be spread through direct contact with an infected pig. PCV2 is the single-stranded DNA (ssDNA) virus with the highest mutation and recombination rate of all single-stranded DNA (ssDNA) viruses. PCV is one of the most important infectious agents affecting pig productivity worldwide.
Furthermore, according to Henna's article published in MDPI Viruses in January 2021, the global prevalence and status of PCV have resulted in a seropositivity rate of 20-80% in pigs, as well as a very high incidence rate of 60%, with a culling rate of 40% in severely affected pig farms.
Commercially available PCVAD vaccines can be of many types, mainly based upon the dosage, packaging size, age of the pig it is used on, and virus type. Some of the major brands manufacturing and selling porcine vaccines for PCVAD, globally, are Boehringer Ingelheim, Merck, and Zoetis, among others. The first FLEX Family swine vaccine for PCV2 protection in a single injection was Ingelvac CircoFLEX, by Boehringer Ingelheim. Hence, it is one of the revolutionary PCV2 vaccines on the market.
Thus, the segment is anticipated to witness significant growth over the forecast period due to the abovementioned factors.
North America Holds a Significant Market Share
Increasing pork consumption, the growing prevalence of various swine diseases, and rising per capita animal healthcare expenditure are the factors the United States is expected to retain its large market share.
In the United States, advancements in vaccine development include the development of live vector vaccines, non-replicating recombinant antigen vaccines, nucleic acid-mediated vaccines, and live-gene-deleted vaccines. Moreover, technological advances in the vaccine field and well-established healthcare infrastructure are also considerably fueling the regional market's growth. For instance, in March 2022, Boehringer Ingelheim launched the porcine parvovirus vaccine ReproCyc ParvoFLEX which provides safe, efficacious protection for healthy sows and gilts six months of age or older against reproductive failure caused by porcine parvovirus.
Furthermore, according to the Agricultural Economic Insights (AEI) report, meat consumption in the United States increased in 2020 when studied from 1970 to 2020. Although poultry, beef, and pork consumption pattern broadly vary, it increases the risk of swine diseases.
Thus, the market is expected to witness significant growth during the forecast period due to the abovementioned factors.
